Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification. by Seed, G et al.
 1 
Title:  
Gene Copy Number Estimation From Targeted Next Generation Sequencing 
Of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification.  
 
 
Authors: 
George Seed1*, Wei Yuan1*, Joaquin Mateo1, Suzanne Carreira1, Claudia 
Bertan1, Maryou Lambros1, Gunther Boysen1, Roberta Ferraldeschi1,2, 
Susana Miranda1, Ines Figueiredo1, Ruth Riisnaes1, Mateus Crespo1, Daniel 
Nava Rodrigues1, Eric Talevich4, Dan Robinson3, Lakshmi P Kunju3, Yi-Mi 
Wu3, Robert Lonigro3, Shahneen Sandhu1,2, Arul Chinnayan4, Johann de 
Bono1,2. 
 
AFFILIATIONS: 
1. The Institute of Cancer Research, London, United Kingdom; 2. The Royal 
Marsden NHS Foundation Trust, London, United Kingdom; 3. Michigan 
Centre for Translational Pathology, Ann Arbor, Michigan, USA; 4. University of 
California San Francisco, San Francisco, USA. 
* Indicates these authors contributed equally. 
 
Running Title: 
Targeted-seq and copy-number analysis of CRPC biopsies. 
 
*CORRESPONDING AUTHOR:  
Professor Johann S de Bono, MB ChB, MSc, FRCP, PhD, FMedSci 
Regius Professor of Experimental Cancer Medicine 
Division of Clinical Studies, The Institute of Cancer Research 
The Royal Marsden NHS Foundation Trust 
London SM2 5NG 
United Kingdom 
Telephone: +44 (0)2087224028;   Fax: +44 (0)2086427979 
Email: johann.de-bono@icr.ac.uk  
 
ACKNOWLEDGEMENTS: This study was supported by Cancer Research 
UK, Prostate Cancer UK, and the Stand Up To Cancer – Prostate Cancer 
Foundation Prostate Dream Team Translational Research Grant (Grant 
Number: SU2C-AACR-DT0712). Stand Up To Cancer is a program of the 
Entertainment Industry Foundation. Research grants are administered by the 
American Association for Cancer Research, the Scientific Partner of SU2C. 
Support was also provided by an Experimental Cancer Medicine Centre grant 
and a Medical Research Council/Prostate Cancer UK fellowship to J. Mateo. 
G. Seed was supported by a Prostate Cancer UK PhD studentship (TLD-S15-
006), and G. Boysen was supported by a Marie Curie International Incoming 
Fellowship (625792). This study was also supported by research funding from 
the EU FP7 project CTCTrap #305341. We thank the staff at the Prostate 
Targeted Therapy Group and all the patients who agreed to participate in this 
study. 
Research. 
on August 14, 2017. © 2017 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on July 27, 2017; DOI: 10.1158/1078-0432.CCR-17-0972 
 2 
Statement of Translational Relevance  
Detection of oncogenic genomic aberrations has led to novel therapeutic 
strategies for treating cancer. We recently showed that 20-30% of metastatic 
prostate cancers have deleterious defects in DNA repair machinery affecting 
genes such as BRCA2, ATM, PALB2, BRCA1 and CDK12. These aberrations 
are associated with sensitivity to PARP inhibitors. Robust methods are 
needed to identify these tumor subtypes. We have previously described a 
targeted next generation sequencing (NGS) method that identifies single 
nucleotide variants (SNVs) and copy number aberrations, with precision, from 
formalin-fixed, paraffin-embedded. tumor biopsy samples. We now describe 
the bioinformatics pipeline for this robust high throughput, cost efficient and 
rapid solution. We have implemented these methods into clinical trial 
protocols to enable patient stratification.  
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Abstract 
Purpose 
Precise detection of copy number aberrations (CNAs) from tumor biopsies is 
critically important to the treatment of metastatic prostate cancer. The use of 
targeted panel next generation sequencing (NGS) is inexpensive, high 
throughput and easily feasible, allowing single nucleotide variant calls, but 
CNA estimation from this remains challenging..  
 
Experimental Design 
We evaluated CNVkit for CNA identification from amplicon-based targeted 
NGS in a cohort of 110 fresh castration resistant prostate cancer biopsies, 
and used capture based whole exome sequencing (WES), array comparative 
genomic hybridization (aCGH), and fluorescent in situ hybridization (FISH) to 
explore the viability of this approach. 
 
Results 
We showed that this method produced highly reproducible CNA results 
(r=0.92), with the use of pooled germline DNA as a coverage reference 
supporting precise CNA estimation. CNA estimates from targeted next 
generation sequencing were comparable with WES (r=0.86) and aCGH 
(r=0.7); for key selected genes (BRCA2, MYC, PIK3CA, PTEN and RB1) CNA 
estimation correlated well with WES (r = 0.91) and aCGH (r = 0.84) results.  
 
The frequency of CNAs in our population was comparable to that previously 
described (ie deep deletions: BRCA2 4.5%; RB1 8.2%; PTEN 15.5%; 
amplification: AR 45.5%; gain: MYC 31.8%). We also showed, utilizing FISH, 
that CNA estimation can be impacted by intra-tumor heterogeneity and 
demonstrated that tumor microdissection allows NGS to provide more precise 
CNA estimates. 
 
Conclusion 
Targeted NGS and CNVkit based analyses provide a robust, precise, high 
throughput and cost effective method for CNA estimation for the delivery of 
more precise patient care.   
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Introduction:  
Prostate cancer is a highly heterogeneous disease with distinct genomic 
underpinnings1 and generally presents a modest number of single point 
mutations and small insertions and deletions (indels) at approximately four per 
megabase5,6, but frequently has large-scale copy number and structural 
alterations7,8.  We recently showed that 20-30% of prostate tumours bear 
defects in DNA repair genes that render them sensitive to treatment with 
PARP inhibition, and that these are commonly mediated through deletions in 
these tumor suppressors9.  
 
High throughput, inexpensive, multiplex biomarker assays for molecular 
stratification are needed to guide therapeutic choices and support clinical trial 
design. While high-coverage whole exome or genome sequencing can reliably 
assess tumour genomics, cost and bioinformatic demands currently restrict 
their routine clinical implementation to stratify patients for treatment. Targeted 
next-generation sequencing represents an opportunity for implementing 
genomics in clinical practice with the advantages of a rapid turnaround time, 
lower cost and the ability to concurrently analyse multiple genes with a limited 
bioinformatic analysis burden. Existing approaches to call somatic and 
germline single nucleotide variants and short indels from targeted sequencing 
data are well-established and have led to a number of FDA biomarker-
dependent drug approvals including the PARP inhibitor olaparib in the last 
decade10,11. However, in the case of PARP inhibition for homologous 
recombination repair defective cancers, screening for tumours with these DNA 
repair defects relies on detecting gene copy number changes.  
 
In this study, we identify gene copy number aberrations (CNA), based on 
targeted amplicon sequencing of a focused biomarker gene panel dedicated 
to identifying DNA repair defects. We used a patient cohort of metastatic 
castration-resistant prostate cancer to explore the utility of this approach. This 
targeted gene panel focused on the study of 113 genes important to DNA 
repair machinery including BRCA2, BRCA1, ATM, PALB2 and CDK12 as well 
as other important potentially actionable prostate cancer genes including AR, 
SPOP, PIK3CA, PTEN, AKT1, AKT2 and MYC.1,9   
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Methods:  
Patient Selection and Sample Preparation 
Patient tumour (biopsies) and germline (buccal swab and saliva) samples 
were collected as part of the Royal Marsden ethics committee approved 
CCR2472 protocol. Samples were collected, annotated, stored and reviewed 
as described previously9. All samples were collected between 25/07/2015 and 
17/10/2016. 
 
Briefly, biopsies were paraffin embedded, DNA from biopsies was extracted 
using the QIAamp DNA FFPE Tissue kit (Qiagen), Quant-iT Picogreen High-
Sensitivity double-stranded DNA (dsDNA) Assay Kits (Invitrogen, 
ThermoFisher Scientific Co) and QC check by FFPE QC kit (Illumina).   
 
Targeted Panel Design 
A customised Generead v2 DNAseq Panel (Qiagen) panel was used for 
library construction; the exonic regions of 113 genes were included in the 
targeted panel, these being selected for being potentially actionable and/or 
involved in DNA damage repair processes and/or in prostate carcinogenesis9 
(Supplemental Table 1).  The panel covered ~564kb of the human genome, 
and each of the 113-genes was covered by an average of 18.69 probes (sd 
13.64).  
 
Targeted and Exome Sequencing 
Targeted amplicon sequencing was performed using the Illumina MiSeqTM 
platform following the manufacturers’ protocol. FASTQ files were generated 
using the Illumina MiSeq Reporter v2.5.1.3TM 12,13. Reads were aligned to the 
human reference genome (hg19) using BWA. Whole exome sequencing was 
performed at the University of Michigan as previously described1. 
 
FastQC (v0.11.2) and Samtools (0.1.19) were used to assess sequencing 
quality. Targeted sequencing samples were excluded from copy number 
analysis on the basis of: insufficient (<0.5 million) total read counts, low 
(<95%) percentage of properly paired reads, and low (<99.99%) percentage 
of on-target reads. Exome sequencing samples were rejected if the FastQC 
per-base quality score for 75% of the reads was less than Q20 over the first 
80 bases, and alignment quality was monitored with Picard, as described 
previously1.  
 
Copy Number Aberrations 
We used the software CNVkit (v0.3.5)14 to analyse sequencing coverage and 
copy number in the aligned sequencing reads from targeted amplicon 
sequencing of tumour and germline samples. Sequencing coverage of 
targeted regions in germline samples was assessed and used to create 
pooled reference data that included the technical variability at each covered 
region. Regions that were poorly captured or mapped were masked from 
further analysis. The analyses of germline samples were also performed with 
CNVkit to validate sample quality. The read depths of tumour samples were 
accessed, normalised (corrected for GC content, target footprint size and 
spacing, and repetitive sequences), and individually compared to the 
reference, and the circular binary segmentation (CBS) algorithm15 was used 
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to infer copy number segments. Very small copy changes (≤3 bins) were 
treated as artifacts. Poor samples were also identified through high (>0.8) 
values of the segment inter-quartile range (IQR), a metric for the spread of 
bin-level copy ratios within each segment following application of the CBS 
algorithm. Copy number segments were annotated to genes, and regions 
bearing a Log2 ratio of at least ±0.4 were identified as suggestive of shallow 
deletions or gains14. Segments with Log2 < -1.2 were classified as deep 
deletions, and those with Log2 > 2 were classified as amplifications.  
Experimental noise was identified as a Log2 ratio standard deviation of  ~0.2.  
 
Whole-exome sequencing CNA data was extracted from a previously reported 
Su2C-PCF dataset1. Briefly, Log2 ratios were derived on a per-gene basis 
from circular-binary segmented, Lowess-normalised Log2 transformed 
coverage ratio between each tumour and matched normal sample.   
 
Array Comparative Genomic Hybridization 
Tumour DNA from prostate cancer patients and male reference DNA from 
Agilent were amplified using Sigma WGA2 kit (Sigma-Aldrich, MO, USA) 
according to the manufacturer’s recommendations and the amplified DNA was 
quantified by the Qubit fluorometric quantitation method (Thermo Fisher 
Scientific, MA, USA). 500ng of amplified tumour DNA was then fluorescently 
labeled with Cy5, and male reference DNA labeled with Cy3, using the 
SureTag Complete DNA Labeling Kit (Agilent Technologies CA, USA). 
Labeled DNA was subsequently hybridised utilizing the Agilent SurePrint G3 
Human CGH Microarray Kit, 4x180K according to the manufacturer’s 
instructions. The slides were then scanned and analysed using the 
CytoGenomics Software v 4.0.3.12 (Agilent Technologies CA, USA). In order 
to compare aCGH and NGS results we used the Log2 ratio of the aCGH 
segments that overlap with genes present in the NGS panel. Genes not part 
of a copy-altered segment were included in the analysis by using the mean 
Log2 ratio for probes, if the value was no greater than 0.25. Genes on the X-
chromosome were excluded from comparison with results from the male-
reference-based panel data since a female reference was used for aCGH.  
 
FISH 
RB1 FISH was performed using a standard FFPE hybridisation method16 on 
3-µM FFPE tissue slices adjacent to hematoxylin and eosin sections that were 
confirmed to contain a minimum of 50 intact cells. Briefly, RB1 status was 
determined using Vysis LSI 13 RB1 (13q14) probe (Catalogue # 08L65-020; 
Abbott Laboratories, Abbott Park, Illinois, U.S.A.) and a reference probe Vysis 
13q34 (Catalogue # 05N34-020; Abbott Laboratories, Abbott Park, Illinois, 
U.S.A.). 19 z-stacks were used to assess cell status.   
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Results: 
Metastatic Prostate Cancer Sample Characteristics 
Freshly collected metastatic castration-resistant prostate cancer (mCRPC) 
biopsies (n=110) were collected from patients with progressing disease 
(Supplemental table 2) and assessed for copy-number changes by 
sequencing with our targeted panel. Germline DNA samples (buccal swab) 
were taken from 34 consenting patients to use as a baseline reference and for 
additional analyses. Tumour biopsies were from: bone (49.1%), lymph nodes 
(35.5%), liver (9.1%), soft tissue disease (3.6%) and transurethral resection of 
the prostate (TURP; 3.6%).  
 
CNA Estimation Reproducibility   
Accurately assessing the depth of coverage of genes can be biased by high 
GC content and repetitive regions14,17, so we first evaluated CNA 
reproducibility on a per-gene basis between technical replicates. Thirteen 
samples were sequenced in duplicate to assess technical variation, twelve of 
these duplicate datasets included repeated library preparation from the same 
DNA extraction, while one involved resequencing of the same library twice.  
 
We identified 15 genes that produced less concordant results between 
replicates, including five genes with insufficient number of targeted regions 
(four or less probes) per gene (NRAS, NFKBIA, FANCF, FAM46C, CDKN1B), 
and ten (MAP2K2, CDKN2A, HRAS, RECQL4, NOTCH1, FGFR3, STK11, 
TSC2, SMARCA4, AXIN1) that contained repetitive or polymorphic exonic 
regions that impeded accurate read alignment and possessed high coverage 
variability (Supplementary Figure 1). These genes were excluded from 
downstream CNA analyses. 
 
Following removal of the aforementioned genes, CNA estimates between 
duplicates showed high correlation (Pearson r correlation coefficient = 0.92) 
(Figure 1a). All genes with deep deletions (Log2 ratio -1.2) or amplifications 
(Log2 ratio > 2) had a similar (at least +- 0.4) CNA estimation replicated in the 
duplicate sample. 95% of samples with a log2 ratio change of at least +- 0.4 
had a similar result in the duplicate  
 
The use of a matched germline sample is commonly used for identifying 
deviations in coverage ratios, so we sought to compare this with our pooled 
reference approach. For the pooled reference, we sequenced 34 unmatched 
germline samples, and assessed the depth of coverage as described 
previously14. Regions with low variability were identified in the pooled 
reference, and used to weight downstream CNA estimates14. This approach 
produced a highly similar result (overall Pearson r = 0.93) when compared 
with the CNA estimation approach using a matched normal as reference, 
when matched normal samples were available (Figure 1b); however the CNA 
estimation confidence score (IQR value) was improved when using pooled 
germline samples (paired t test p = 0.05). This was in line with other reports17 
that indicated that using pooled germline sequencing data as reference 
offered a robust method to identify gene copy number aberrations.  
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CNA Validation by exome sequencing and aCGH 
We cross-compared copy number Log2 ratios for all evaluable genes on the 
targeted panel with Log2 ratios generated by exome-sequencing (n=13) 
(Figure 1c), resulting in a Pearson r correlation coefficient of 0.86. Moreover, 
of all the genes with a Log2 ratio <-1.2 by targeted sequencing, in keeping 
with putative ‘deep’ deletions, exhibited a similar (at least +- 0.4) result in the 
exome-sequencing. For example, one sample bore AR amplification (Log2 
ratio 5.7 in targeted NGS and 4.91 in WES) alongside WRN deletion (-1.53 
versus -1.17) and ATM deletion (-0.68 versus -0.56). We also compared Log2 
ratios from aCGH segments (n=9) with gene copy number estimations by 
panel NGS among the genes covered by both platforms, and found log2 ratios 
were also concordant (Figure 1d), with a Pearson r value of 0.7.  
 
We then sought to further validate copy-number calls for specific genes of 
clinical relevance such as BRCA2, MYC, PIK3CA, PTEN and RB1 (Figures 
1e and 1f). For these genes, we found that our panel produced results highly 
concordant with exome-sequencing and aCGH data; with Pearson r values of 
0.91 and 0.84 respectively. All clinically relevant deletions of BRCA2 in 
samples with exome or aCGH data were also identified in our panel results 
(Table 1).  
 
CNA Profiles in CRPC 
In the analyses of this cohort of advanced prostate cancer samples, the 
prevalence of the CNAs detected with this assay was consistent with that of 
previously reported studies (Figure 2). CNAs of AR (amplification; Log2 > 2) 
were found in 45.5% (50/110) of tumour samples. Broad deletions of 
chromosome 131 involving the shared loss of BRCA2 and RB1 were detected 
as previously described with 23/26 (88%) of samples with any BRCA2 loss 
also having some loss of RB1, while overall 23/66 (34.8%) of samples with 
RB1 loss had loss of BRCA2) (Figure 2a).  
 
Overall, the evaluation of the deep deletions of commonly aberrant CRPC 
genes revealed results in keeping with previous reports from two recent 
studies of CRPC genomics1,2; PTEN genomic deep deletions were detected in 
17/110 (15.5%), BRCA2 deep deletion in 5/110 (4.5%), and RB1 deep 
deletion in 9/110 (8.2%) of CRPC samples. In addition, gain of the MYC locus 
was found in 36/110 (32.7%). We found that our values were in line with 
expected values (Figure 2b).  
 
Exploring tumour purity and heterogeneity 
In order to further explore how tumour purity altered the capacity of the assay 
to detect CNAs, we pursued the serial dilution of tumour DNA acquired from a 
sample estimated by pathology review as having 80% tumour content, with 
same-patient germline DNA. This sample harboured a somatic, BRCA2 
homozygous deletion (independently confirmed WES). We then sequenced 
the resulting dilutions (Figure 3a) and found that homozygous deletions were 
easily distinguishable with tumour content purities >60%, and that clonal 
CNAs were detectable with purity as low as 30%.  
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We also performed micro-dissection of a tumour biopsy (pathologist tumour 
purity estimate ~40%) bearing borderline BRCA2 homozygous deletion (Log2 
ratio of -1.15), and re-sequenced the resulting tumour-enriched sample (purity 
estimate ~80%). This step further shifted the CNA estimates away from 
normal, with the Log2 ratio for BRCA2 dropping to -2.82, an unambiguous 
deletion (Figure 3b). 
 
The Log2 copy ratios estimated from sequencing a bulk of cells, as in our 
protocol, can be biased by tumour sample heterogeneity. To assess this 
relationship, we performed FISH assays of the RB1 gene, counting the 
number of cells where each copy number (0 through 3+) was observed 
(Figure 3c). Our results showed an association between the proportion of 
cells with 1 or 0 copies of RB1 (hemizygous or homozygous deletion) and 
putative copy loss inferred from our targeted sequencing panel (unpaired t-
test p-value 0.02, n=18, df=15.884). However, the full complexity of 
aneuploidy in individual tumour cells is masked by bulk tissue sequencing, 
which effectively averages the estimated DNA content across all cells in a 
sample. FISH analyses revealed that many tumour samples contained a 
mixture of cells with different copy number changes at the RB1 locus, in highly 
heterogeneous cell populations (Supplemental Figure 2). 
 
 
 
 
 
Discussion 
The ability to rapidly, inexpensively, and accurately identify cancers with 
actionable genomic defects in tumour biopsies is now becoming critically 
important for advanced prostate cancer care. We have previously shown that 
a proportion of metastatic castration-resistant prostate cancers have DNA 
repair defects and are sensitive to treatment with PARP inhibitors9, with 
emerging studies of platinum-based chemotherapies also indicating important 
antitumour activity in this population18. These and other data support further 
studies of genomic stratification for treatment selection for patients suffering 
from mCRPC. Here we demonstrate the analytic validation and clinical use of 
a targeted next generation sequencing assay that allows for copy-number 
screening for predictive biomarkers of response, enabling the integration of 
more precise patient stratification into trial design.  
 
Our method reliably estimates gene copy number changes from amplicon 
based targeted next generation sequencing with the acquired results being 
comparable to widely used assays including exome sequencing, array 
comparative genomic hybridization, digital droplet PCR and FISH.19. Critically, 
the data processing time for this panel-based CNA estimation is substantially 
shorter of that for exome sequencing and can be easily completed even with a 
personal computer. In addition, we have confirmed that using pooled germline 
samples as a reference can produce equivalent and robust results to utilizing 
matched normal samples. This feature provides the possibility of diagnosing 
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patients with only tumour samples for whom germline DNA is not available, 
and can dramatically reduce the overall sequencing costs of large studies.  
 
This approach is currently being applied in the TOPARP-B (NCT01682772) 
study as part of an ongoing attempt to clinically qualify DNA repair pathway 
aberrations as a predictive biomarker for treatment with PARP inhibition with 
olaparib18. However, this assay has utility beyond this study. The gene panel 
we utilised covers several key genomic aberrations that are of emerging 
interest as possible clinical predictive biomarkers that may be actionable in 
prostate cancer, including loss of PTEN, gain of PIK3CA (both may sensitise 
tumours to PI3K/AKT pathway inhibition20,21), and amplification of MYC (MYC 
driven tumours have been reported to sensitize to AURA and BET inhibition 
and can result in replication stress22). Prospectively identifying tumours 
bearing these CNAs and other deleterious mutations, utilizing such validated 
methods, is likely to become critically important in defining future treatment 
strategies for this commonest of male cancers. 
 
We explored the functional limits of assessing CNAs and found that our 
pipeline can confidently estimate deletion when tumour content is reduced to 
60% (homozygous and heterozygous). As tumour content decreases, the 
pipeline struggles to differentiate between homozygous and heterozygous 
deletions, and we estimate that interpreting results from samples with <30% 
purity may be extremely challenging for targeted NGS panels. We have 
shown, however, that the use of micro-dissection to enrich tumour content 
offers a possible solution to resolve these issues.  
 
This approach also suffers from the nature of amplicon based next generation 
sequencing, including difficulty identifying precise breakpoints, very focal 
gains or deletions, unequal amplification among genes and coverage variation 
across polymorphic repeat regions. Furthermore, because the number of 
single nucleotide variants identified in targeted panels will be much lower 
when compared to exome or whole genome sequencing, SNV allele 
frequencies may not be sufficient to assist with copy number estimation or to 
detect allelic imbalance.  
 
It is important to note that we did not systematically compare software tools in 
this study, and that different clinical requirements will require individual 
optimisations. As the field develops, other software tools will emerge to 
improve the precision of CNA identification in targeted sequencing, and 
independent validations will be critical in guiding further work.  
 
In conclusion, we have described the validation and clinical application of an 
assay evaluating 100 genes utilised to assess both deleterious tumour gene 
copy number, and mutations, from targeted next generation sequencing of 
prostate cancer samples from the most common metastatic sites, including 
bone biopsies. We have validated these results by orthogonal methods 
including not only exome sequencing, but also aCGH and FISH. Such 
targeted panel NGS assays are likely to become central to future patient care 
in cancer therapy.  
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Figure Legends 
Figure1 
Copy number estimation results by targeted NGS and the described 
bioinformatic method were highly reproducible. Correlations of Log2 results 
(overplotted) shown from: Figure 1a) Replicate samples (n = 13); Figure 1b) 
Matched germline reference (25 pairs available) against pooled germline 
reference. Pearson r values presented. Comparing tools for generating 
informative Log2 ratios showed that targeted panel NGS of CRPCs produced 
valid results for identification of CNAs when compared with orthogonal 
methods. Shown are correlations of Log2 results (overplotted) from: Figure 
1c) Panel data with exome data (n = 13); and Figure 1d) Panel data with 
aCGH results (n = 9). Pearson r values depicted. CNA orthogonal validation 
focusing on selected genes of therapeutic relevance to CRPC presented as 
Log2 ratios in comparison with exome (Figure 1e) and aCGH (Figure 1f) data 
from the same samples compared to panel data. Colors indicate gene: 
BRCA2 = red, MYC = orange, PIK3CA = dark blue, PTEN = light blue, RB1 = 
yellow. Pearson r values are shown.  
 
Figure 2a. 
Binned heatmap of copy number aberrations for all evaluated (n = 110) 
samples with colors defined by log2 ratio thresholds (dark blue, < -1.2; light 
blue, < -0.4; pink, > 0.4; red, > 2). Rows and columns clustered by complete 
Euclidean distance for visualization purposes only. Commonly deleted genes 
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such as PTEN, RB1 and BRCA2 cluster towards the left, while commonly 
amplified genes such as AR, MYC, BRAF and KRAS trend to the right. Genes 
which are closely located in chromosomal coordinates (eg CHEK2 and NF2, 
BLM and MAP2K1,RB1 and BRCA2) often share similar copy-number 
aberrations. 
 
Figure 2b 
Scatter plot showing that the percentage of samples with specific copy-
number changes in our targeted sequencing cohort was similar to two recently 
published studies of CNAs in CRPC1,2. Colors indicate type of aberration (red 
= amplification, pink = gain, blue = deletion). Shape of points indicate study 
data source. Data was derived from copy number frequency data publicly 
available from cbioportal3,4, retrieved at 17/11/2016. 
 
Figure 3a 
Serial dilution of a tumour sample with matched germline DNA and 
resequencing highlights functional limits of copy number detection. 
Homozygously deleted (BRCA2, PTEN – dark blue), hemizygously deleted 
(RB1 – light blue), copy-neutral (SPOP – grey) and copy-gained (PIK3CA – 
pink) genes are shown.  
 
Figure 3b 
Micro-dissection of a biopsy to enrich tumour content emphasizes a BRCA2 
deletion, as the segment Log2 ratio (orange line) shifts from -1.15 to -2.82. 
Also shown are individual exon-level copy ratios (blue points), from which the 
segment is assigned.  
 
 
 
Figure 3c 
Stacked bar plot showing RB1-FISH results for 18 samples (50 cells each), 
with colors indicating observable copies of RB1 for individual cells. Navy, 0 
copies; light blue, 1 copy; white, 2 copies; pink, >2 copies. Black bar indicates 
samples which had a deletion of any kind reported by our targeted NGS 
protocol.  
 
 
Table 1 
Validation of BRCA2 results from targeted panel CNV analysis with either 
whole-exome (E) sequencing or array (A) comparative genome hybridisation, 
log2 ratios are shown. Colours indicate direction of shift away from 0, with 
losses represented by blue and gains represented by red.  
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Sample 
Panel 
BRCA2 
Exome aCGH 
BRCA2 
p.4.1 -0.670 -0.845 
 p.5.0 0.262 0.46 
 p.7.0 -0.542 -0.611 
 p.8.0 -0.152 -0.095 
 p.9.0 -0.682 -0.442 
 p.13.0 -0.109 -0.074 
 p.14.1 -0.663 -0.815 
 p.15.0 -0.546 -0.639 
 p.18.0 0.036 0.057 
 p.20.0 0.377 0.838 
 p.22.0 -0.101 -0.101 
 p.23.0 -0.259 -0.277 
 p.25.0 -0.633 -0.52 
 p.39.0 -0.324 
 
-0.389 
p.41.0 0.056 
 
-0.264 
p.45.0 -0.139 
 
-0.17 
p.110.0 -0.576 
 
-0.516 
p.69.0 -1.419 
 
-1.665 
p.98.0 0.102 
 
0.008 
p.102.0 0.065 
 
-0.128 
p.104.0 0.75 
 
0.321 
p.38.2 0.468 
 
0.003 
Table 1 
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